<?xml version='1.0'?><!DOCTYPE Annotation PUBLIC "//GENIA//DTD GENIA ANNOTATION EVENT 2.0//EN_Modified" "../ModifiedGENIAtypes/Modified_GENIA_event_20.dtd"><Annotation annotates="http://www.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;retmode=xml&amp;rettype=medline&amp;id=10101034" created="15/05/2006" creator="Yo Shidahara"><PubmedArticleSet><PubmedArticle><MedlineCitation>
<PMID>10101034</PMID>
<Article>
<ArticleTitle>
<sentence id="S1"><term id="T58" sem="Other">Inhibition</term> of <term id="T1" lex="cyclooxygenase-2_expression" sem="Other"><term id="T2" lex="cyclooxygenase-2" sem="Protein_molecule">cyclooxygenase-2</term> expression</term> by <term id="T3" lex="4-trifluoromethyl_derivative" sem="Organic_compound_other">4-trifluoromethyl derivatives</term> of <term id="T4" lex="salicylate" sem="Organic_compound_other">salicylate</term>, <term id="T5" lex="triflusal" sem="Organic_compound_other">triflusal</term>, and its <term id="T6" lex="deacetylated_metabolite" sem="Organic_compound_other">deacetylated metabolite</term>, <term id="T7" lex="2-hydroxy-4-trifluoromethylbenzoic_acid" sem="Organic_compound_other">2-hydroxy-4-trifluoromethylbenzoic acid</term>.</sentence>
<event KT="Other" id="E1">
<type class="Gene_expression"/>
<theme idref="T2"/>
<clue>Inhibition of cyclooxygenase-2 <clueType>expression</clueType> by 4-trifluoromethyl derivatives of salicylate, triflusal, and its deacetylated metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid.</clue>
</event>
<event KT="Investigation" id="E2">
<type class="Negative_regulation"/>
<theme idref="E1"/>
<cause idref="T5"/>
<clue><clueType>Inhibition</clueType> <linkTheme>of</linkTheme> cyclooxygenase-2 expression <linkCause>by</linkCause> 4-trifluoromethyl derivatives of salicylate, triflusal, and its deacetylated metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid.</clue>
</event>
<event KT="Investigation" id="E3">
<type class="Negative_regulation"/>
<theme idref="E1"/>
<cause idref="T7"/>
<clue><clueType>Inhibition</clueType> <linkTheme>of</linkTheme> cyclooxygenase-2 expression <linkCause>by</linkCause> 4-trifluoromethyl derivatives of salicylate, triflusal, and its deacetylated metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid.</clue>
</event>
</ArticleTitle>
<Abstract>
<AbstractText>
<sentence id="S2">The therapeutic potential of drugs that block the induction of <term id="T8" lex="cyclooxygenase-2" sem="Protein_molecule">cyclooxygenase-2</term> has been emphasized.</sentence>
<sentence id="S3">When two <term id="T9" lex="4-trifluoromethyl_salicylate_derivative" sem="Organic_compound_other">4-trifluoromethyl salicylate derivatives</term> [<term id="T10" lex="2-acetoxy-4-trifluoromethyl-benzoic_acid" sem="Organic_compound_other">2-acetoxy-4-trifluoromethyl-benzoic acid</term> (<term id="T11" lex="triflusal" sem="Organic_compound_other">triflusal</term>) and its <term id="T12" lex="deacetylated_metabolite" sem="Organic_compound_other">deacetylated metabolite</term> <term id="T13" lex="2-hydroxy-4-trifluoromethylbenzoic_acid" sem="Organic_compound_other">2-hydroxy-4-trifluoromethylbenzoic acid</term> (<term id="T14" lex="HTB" sem="Organic_compound_other">HTB</term>)] were compared with aspirin and sodium salicylate as <term id="T15" lex="cyclooxygenase-2" sem="Protein_molecule">cyclooxygenase-2</term> (COX-2) inhibitors, we observed that in <term id="T16" lex="bacterial_lipopolysaccharide-activated_human_blood" sem="Tissue_natural">bacterial lipopolysaccharide-activated human blood</term>, <term id="T17" lex="triflusal" sem="Organic_compound_other">triflusal</term>, <term id="T18" lex="aspirin" sem="Organic_compound_other">aspirin</term>, and <term id="T19" lex="HTB" sem="Organic_compound_other">HTB</term>, but not <term id="T20" lex="sodium_salicylate" sem="Organic_compound_other">sodium salicylate</term>, inhibited <term id="A2" sem="Protein_molecule">COX-2</term>-mediated <term id="T22" sem="Other"><term id="A3" sem="Organic_compound_other">prostaglandin E2</term> (<term id="T23" lex="PGE2" sem="Organic_compound_other">PGE2</term>) production</term> (IC50 = 0.16, 0.18, 0.39, and &gt;10 mM, respectively).</sentence>
<event KT="Other" id="E6">
<type class="Metabolism"/>
<theme idref="T23"/>
<clue>When two 4-trifluoromethyl salicylate derivatives [2-acetoxy-4-trifluoromethyl-benzoic acid (triflusal) and its deacetylated metabolite 2-hydroxy-4-trifluoromethylbenzoic acid (HTB)] were compared with aspirin and sodium salicylate as cyclooxygenase-2 (COX-2) inhibitors, we observed that in bacterial lipopolysaccharide-activated human blood, triflusal, aspirin, and HTB, but not sodium salicylate, inhibited COX-2-mediated prostaglandin E2 (PGE2) <clueType>production</clueType> (IC50 = 0.16, 0.18, 0.39, and &gt;10 mM, respectively).</clue>
</event>
<event KT="Other" id="E7">
<type class="Positive_regulation"/>
<theme idref="E6"/>
<cause idref="A2"/>
<clue>When two 4-trifluoromethyl salicylate derivatives [2-acetoxy-4-trifluoromethyl-benzoic acid (triflusal) and its deacetylated metabolite 2-hydroxy-4-trifluoromethylbenzoic acid (HTB)] were compared with aspirin and sodium salicylate as cyclooxygenase-2 (COX-2) inhibitors, we observed that in bacterial lipopolysaccharide-activated human blood, triflusal, aspirin, and HTB, but not sodium salicylate, inhibited COX-2-<clueType>mediated</clueType> prostaglandin E2 (PGE2) production (IC50 = 0.16, 0.18, 0.39, and &gt;10 mM, respectively).</clue>
</event>
<event id="E8">
<type class="Negative_regulation"/>
<theme idref="E7"/>
<cause idref="T17"/>
<clue>When two 4-trifluoromethyl salicylate derivatives [2-acetoxy-4-trifluoromethyl-benzoic acid (triflusal) and its deacetylated metabolite 2-hydroxy-4-trifluoromethylbenzoic acid (HTB)] were compared with aspirin and sodium salicylate as cyclooxygenase-2 (COX-2) inhibitors, we <clueKT>observed</clueKT> that <clueLoc>in bacterial lipopolysaccharide-activated human blood</clueLoc>, triflusal, aspirin, and HTB, but not sodium salicylate, <clueType>inhibited</clueType> COX-2-mediated prostaglandin E2 (PGE2) production (IC50 = 0.16, 0.18, 0.39, and &gt;10 mM, respectively).</clue>
</event>
<event id="E9">
<type class="Negative_regulation"/>
<theme idref="E7"/>
<cause idref="T18"/>
<clue>When two 4-trifluoromethyl salicylate derivatives [2-acetoxy-4-trifluoromethyl-benzoic acid (triflusal) and its deacetylated metabolite 2-hydroxy-4-trifluoromethylbenzoic acid (HTB)] were compared with aspirin and sodium salicylate as cyclooxygenase-2 (COX-2) inhibitors, we <clueKT>observed</clueKT> that <clueLoc>in bacterial lipopolysaccharide-activated human blood</clueLoc>, triflusal, aspirin, and HTB, but not sodium salicylate, <clueType>inhibited</clueType> COX-2-mediated prostaglandin E2 (PGE2) production (IC50 = 0.16, 0.18, 0.39, and &gt;10 mM, respectively).</clue>
</event>
<event id="E10">
<type class="Negative_regulation"/>
<theme idref="E7"/>
<cause idref="T19"/>
<clue>When two 4-trifluoromethyl salicylate derivatives [2-acetoxy-4-trifluoromethyl-benzoic acid (triflusal) and its deacetylated metabolite 2-hydroxy-4-trifluoromethylbenzoic acid (HTB)] were compared with aspirin and sodium salicylate as cyclooxygenase-2 (COX-2) inhibitors, we <clueKT>observed</clueKT> that <clueLoc>in bacterial lipopolysaccharide-activated human blood</clueLoc>, triflusal, aspirin, and HTB, but not sodium salicylate, <clueType>inhibited</clueType> COX-2-mediated prostaglandin E2 (PGE2) production (IC50 = 0.16, 0.18, 0.39, and &gt;10 mM, respectively).</clue>
</event>
<event assertion="non-exist" id="E11">
<type class="Negative_regulation"/>
<theme idref="E7"/>
<cause idref="T17"/>
<clue>When two 4-trifluoromethyl salicylate derivatives [2-acetoxy-4-trifluoromethyl-benzoic acid (triflusal) and its deacetylated metabolite 2-hydroxy-4-trifluoromethylbenzoic acid (HTB)] were compared with aspirin and sodium salicylate as cyclooxygenase-2 (COX-2) inhibitors, we <clueKT>observed</clueKT> that <clueLoc>in bacterial lipopolysaccharide-activated human blood</clueLoc>, triflusal, aspirin, and HTB, but not sodium salicylate, <clueType>inhibited</clueType> COX-2-mediated prostaglandin E2 (PGE2) production (IC50 = 0.16, 0.18, 0.39, and &gt;10 mM, respectively).</clue>
</event>
<sentence id="S4">However, only <term id="T24" lex="triflusal" sem="Organic_compound_other">triflusal</term> and <term id="T25" lex="aspirin" sem="Organic_compound_other">aspirin</term> inhibited purified <term id="T26" sem="Protein_molecule">COX-2 enzyme</term>.</sentence>
<event id="E12">
<type class="Negative_regulation"/>
<theme idref="T26"/>
<cause idref="T24"/>
<clue>However, only triflusal and aspirin <clueType>inhibited</clueType> purified COX-2 enzyme.</clue>
</event>
<event id="E13">
<type class="Negative_regulation"/>
<theme idref="T26"/>
<cause idref="T25"/>
<clue>However, only triflusal and aspirin <clueType>inhibited</clueType> purified COX-2 enzyme.</clue>
</event>
<sentence id="S5">To test this apparent discrepancy, we realized that <term id="T27" lex="HTB" sem="Organic_compound_other">HTB</term> and <term id="T28" lex="triflusal" sem="Organic_compound_other">triflusal</term> (but neither <term id="T29" lex="aspirin" sem="Organic_compound_other">aspirin</term> nor <term id="T30" lex="salicylate" sem="Organic_compound_other">salicylate</term>) produced a concentration-dependent inhibition of <term id="T31" lex="COX-2_protein_expression" sem="Other"><term id="T32" sem="Protein_molecule">COX-2 protein</term> expression</term> in <term id="T33" lex="peripheral_human_mononuclear_cell" sem="Cell_natural">peripheral human mononuclear cells</term>.</sentence>
<event KT="Other" id="E14">
<type class="Gene_expression"/>
<theme idref="T32"/>
<clue>To test this apparent discrepancy, we realized that HTB and triflusal (but neither aspirin nor salicylate) produced a concentration-dependent inhibition of COX-2 protein <clueType>expression</clueType> in peripheral human mononuclear cells.</clue>
</event>
<event KT="Other" id="E15">
<type class="Negative_regulation"/>
<theme idref="E14"/>
<clue>To test this apparent discrepancy, we realized that HTB and triflusal (but neither aspirin nor salicylate) produced a concentration-dependent <clueType>inhibition</clueType> <linkTheme>of</linkTheme> COX-2 protein expression in peripheral human mononuclear cells.</clue>
</event>
<event KT="Analysis" id="E16">
<type class="Positive_regulation"/>
<theme idref="E15"/>
<cause idref="T27"/>
<clue>To test this apparent discrepancy, we <clueKT>realized</clueKT> that HTB and triflusal (but neither aspirin nor salicylate) <clueType>produced</clueType> a concentration-dependent inhibition of COX-2 protein expression <clueLoc>in peripheral human mononuclear cells</clueLoc>.</clue>
</event>
<event KT="Analysis" id="E17">
<type class="Positive_regulation"/>
<theme idref="E15"/>
<cause idref="T28"/>
<clue>To test this apparent discrepancy, we <clueKT>realized</clueKT> that HTB and triflusal (but neither aspirin nor salicylate) <clueType>produced</clueType> a concentration-dependent inhibition of COX-2 protein expression <clueLoc>in peripheral human mononuclear cells</clueLoc>.</clue>
</event>
<event KT="Analysis" Polarity="Negative" assertion="non-exist" id="E18">
<type class="Positive_regulation"/>
<theme idref="E15"/>
<cause idref="T29"/>
<clue>To test this apparent discrepancy, we <clueKT>realized</clueKT> that HTB and triflusal (but <cluePolarity>neither</cluePolarity> aspirin nor salicylate) <clueType>produced</clueType> a concentration-dependent inhibition of COX-2 protein expression <clueLoc>in peripheral human mononuclear cells</clueLoc>.</clue>
</event>
<event KT="Analysis" Polarity="Negative" assertion="non-exist" id="E19">
<type class="Positive_regulation"/>
<theme idref="E15"/>
<cause idref="T30"/>
<clue>To test this apparent discrepancy, we <clueKT>realized</clueKT> that HTB and triflusal (but neither aspirin <cluePolarity>nor</cluePolarity> salicylate) <clueType>produced</clueType> a concentration-dependent inhibition of COX-2 protein expression <clueLoc>in peripheral human mononuclear cells</clueLoc>.</clue>
</event>
<sentence id="S6">This observation was further confirmed in a <term id="T34" lex="rat_air_pouch_model" sem="Other">rat air pouch model</term> in vivo, in which both <term id="T35" lex="aspirin" sem="Organic_compound_other">aspirin</term> and <term id="T36" lex="triflusal" sem="Organic_compound_other">triflusal</term> inhibited <term id="T37" lex="PGE2_production" sem="Other"><term id="T38" lex="PGE2" sem="Organic_compound_other">PGE2</term> production</term> (ID50 = 18.9 and 11.4 mg/kg p.o., respectively) but only <term id="T39" lex="triflusal-treated_animal" sem="Multicellular_organism_natural"><term id="T40" lex="triflusal" sem="Organic_compound_other">triflusal</term>-treated animals</term> showed a decrease in <term id="T41" lex="COX-2_expression" sem="Other"><term id="T42" lex="COX-2" sem="Protein_molecule">COX-2</term> expression</term>.</sentence>
<event KT="Other" id="E20">
<type class="Metabolism"/>
<theme idref="T38"/>
<clue>This observation was further confirmed in a rat air pouch model in vivo, in which both aspirin and triflusal inhibited PGE2 <clueType>production</clueType> (ID50 = 18.9 and 11.4 mg/kg p.o., respectively) but only triflusal-treated animals showed a decrease in COX-2 expression.</clue>
</event>
<event id="E21">
<type class="Negative_regulation"/>
<theme idref="E20"/>
<cause idref="T35"/>
<clue>This observation was further confirmed <clueLoc>in a rat air pouch model</clueLoc> in vivo, in which both aspirin and triflusal <clueType>inhibited</clueType> PGE2 production (ID50 = 18.9 and 11.4 mg/kg p.o., respectively) but only triflusal-treated animals showed a decrease in COX-2 expression.</clue>
</event>
<event id="E22">
<type class="Negative_regulation"/>
<theme idref="E20"/>
<cause idref="T36"/>
<clue>This observation was further confirmed <clueLoc>in a rat air pouch model</clueLoc> in vivo, in which both aspirin and triflusal <clueType>inhibited</clueType> PGE2 production (ID50 = 18.9 and 11.4 mg/kg p.o., respectively) but only triflusal-treated animals showed a decrease in COX-2 expression.</clue>
</event>
<event KT="Other" id="E24">
<type class="Gene_expression"/>
<theme idref="T42"/>
<clue>This observation was further confirmed in a rat air pouch model in vivo, in which both aspirin and triflusal inhibited PGE2 production (ID50 = 18.9 and 11.4 mg/kg p.o., respectively) but only triflusal-treated animals showed a decrease in COX-2 <clueType>expression</clueType>.</clue>
</event>
<event KT="Analysis" id="E25">
<type class="Negative_regulation"/>
<theme idref="E24"/>
<cause idref="T40"/>
<clue>This observation was further confirmed in a rat air pouch model in vivo, in which both aspirin and triflusal inhibited PGE2 production (ID50 = 18.9 and 11.4 mg/kg p.o., respectively) but only triflusal-<linkCause>treated</linkCause> <clueLoc>animals</clueLoc> <clueKT>showed</clueKT> a <clueType>decrease</clueType> <linkTheme>in</linkTheme> COX-2 expression.</clue>
</event>
<sentence id="S7">This different behavior may be, at least in part, due to the ability of <term id="T43" lex="HTB" sem="Organic_compound_other">HTB</term> and <term id="T44" lex="triflusal" sem="Organic_compound_other">triflusal</term> to block the activation of the transcription factor <term id="T45" lex="nuclear_factor-kappaB" sem="Protein_complex">nuclear factor-kappaB</term> to a higher extent than <term id="T46" lex="aspirin" sem="Organic_compound_other">aspirin</term> and <term id="T47" lex="sodium_salicylate" sem="Organic_compound_other">sodium salicylate</term>.</sentence>
<event KT="Other" id="E26">
<type class="Positive_regulation"/>
<theme idref="T45"/>
<clue>This different behavior may be, at least in part, due to the ability of HTB and triflusal to block the <clueType>activation</clueType> <linkTheme>of</linkTheme> the transcription factor nuclear factor-kappaB to a higher extent than aspirin and sodium salicylate.</clue>
</event>
<event CL="L2" KT="Analysis" id="E27">
<type class="Negative_regulation"/>
<theme idref="E26"/>
<cause idref="T43"/>
<clue>This different behavior may be, at least in part, due to the <clueKT><clueCL>ability</clueCL></clueKT> of HTB and triflusal to <clueType>block</clueType> the activation of the transcription factor nuclear factor-kappaB to a higher extent than aspirin and sodium salicylate.</clue>
</event>
<event CL="L2" KT="Analysis" id="E28">
<type class="Negative_regulation"/>
<theme idref="E26"/>
<cause idref="T44"/>
<clue>This different behavior may be, at least in part, due to the <clueKT><clueCL>ability</clueCL></clueKT> of HTB and triflusal to <clueType>block</clueType> the activation of the transcription factor nuclear factor-kappaB to a higher extent than aspirin and sodium salicylate.</clue>
</event>
<sentence id="S8">Thus, in addition to inhibiting the <term id="T48" lex="COX-2_activity" sem="Other"><term id="T21" sem="Protein_molecule">COX-2</term> activity</term> at therapeutic concentrations, <term id="T49" lex="triflusal" sem="Organic_compound_other">triflusal</term> is able to block through its metabolite <term id="T50" lex="HTB" sem="Organic_compound_other">HTB</term> the expression of new enzyme, and hence the resumption of <term id="T51" lex="PGE2_synthesis" sem="Other"><term id="T52" lex="PGE2" sem="Organic_compound_other">PGE2</term> synthesis</term>.</sentence>
<event id="E29">
<type class="Negative_regulation"/>
<theme idref="T48"/>
<cause idref="T49"/>
<clue>Thus, in addition to <clueType>inhibiting</clueType> the COX-2 activity at therapeutic concentrations, triflusal is able to block through its metabolite HTB the expression of new enzyme, and hence the resumption of PGE2 synthesis.</clue>
</event>
<event KT="Other" id="E30">
<type class="Gene_expression"/>
<theme idref="T42"/>
<clue>Thus, in addition to inhibiting the COX-2 activity at therapeutic concentrations, triflusal is able to block through its metabolite HTB the <clueType>expression</clueType> <linkTheme>of</linkTheme> <corefTheme>new enzyme</corefTheme>, and hence the resumption of PGE2 synthesis.</clue>
</event>
<event CL="L2" KT="Analysis" id="E31">
<type class="Negative_regulation"/>
<theme idref="E30"/>
<cause idref="T50"/>
<clue><clueKT>Thus</clueKT>, in addition to inhibiting the COX-2 activity at therapeutic concentrations, triflusal is <clueCL>able</clueCL> to <clueType>block</clueType> <linkCause>through</linkCause> its metabolite HTB the expression of new enzyme, and hence the resumption of PGE2 synthesis.</clue>
</event>
<event KT="Other" id="E32">
<type class="Metabolism"/>
<theme idref="T52"/>
<clue>Thus, in addition to inhibiting the COX-2 activity at therapeutic concentrations, triflusal is able to block through its metabolite HTB the expression of new enzyme, and hence the resumption of PGE2 <clueType>synthesis</clueType>.</clue>
</event>
<event KT="Other" id="E33">
<type class="Positive_regulation"/>
<theme idref="E32"/>
<clue>Thus, in addition to inhibiting the COX-2 activity at therapeutic concentrations, triflusal is able to block through its metabolite HTB the expression of new enzyme, and hence the <clueType>resumption</clueType> of PGE2 synthesis.</clue>
</event>
<event CL="L2" KT="Analysis" id="E34">
<type class="Negative_regulation"/>
<theme idref="E33"/>
<cause idref="T50"/>
<clue>Thus, in addition to inhibiting the COX-2 activity at therapeutic concentrations, triflusal is <clueCL>able</clueCL> to <clueType>block</clueType> <linkCause>through</linkCause> its metabolite HTB the expression of new enzyme, and <clueKT>hence</clueKT> the resumption of PGE2 synthesis.</clue>
</event>
<sentence id="S9"><term id="T53" lex="triflusal" sem="Organic_compound_other">Triflusal</term> and <term id="T54" lex="HTB" sem="Organic_compound_other">HTB</term> may exert beneficial effects in <term id="A6" sem="Other">processes</term> in which de novo <term id="T55" lex="COX-2_expression" sem="Other"><term id="T56" lex="COX-2" sem="Protein_molecule">COX-2</term> expression</term> is involved and, in a broader sense, in <term id="A5" sem="Other">pathological situations</term> in which <term id="A4" sem="DNA_domain_or_region">genes</term> under <term id="T57" lex="nuclear_factor-kappaB" sem="Protein_complex">nuclear factor-kappaB</term> control are up-regulated.</sentence>
<event KT="Other" id="E35">
<type class="Gene_expression"/>
<theme idref="T56"/>
<clue>Triflusal and HTB may exert beneficial effects in processes in which de novo COX-2 <clueType>expression</clueType> is involved and, in a broader sense, in pathological situations in which genes under nuclear factor-kappaB control are up-regulated.</clue>
</event>
<event KT="Other" id="E42">
<type class="Correlation"/>
<theme idref="E35"/>
<theme idref="A6"/>
<clue>Triflusal and HTB may exert beneficial effects in processes <linkTheme>in which</linkTheme> de novo COX-2 expression is <clueType>involved</clueType> and, in a broader sense, in pathological situations in which genes under nuclear factor-kappaB control are up-regulated.</clue>
</event>
<event CL="L1" KT="Analysis" id="E36">
<type class="Regulation"/>
<theme idref="A6"/>
<cause idref="T53"/>
<clue>Triflusal and HTB <clueKT><clueCL>may</clueCL></clueKT> exert beneficial <clueType>effects</clueType> <linkTheme>in</linkTheme> processes in which de novo COX-2 expression is involved and, in a broader sense, in pathological situations in which genes under nuclear factor-kappaB control are up-regulated.</clue>
</event>
<event CL="L1" KT="Analysis" id="E37">
<type class="Regulation"/>
<theme idref="A6"/>
<cause idref="T54"/>
<clue>Triflusal and HTB <clueKT><clueCL>may</clueCL></clueKT> exert beneficial <clueType>effects</clueType> <linkTheme>in</linkTheme> processes in which de novo COX-2 expression is involved and, in a broader sense, in pathological situations in which genes under nuclear factor-kappaB control are up-regulated.</clue>
</event>
<event KT="Other" id="E38">
<type class="Regulation"/>
<theme idref="A4"/>
<cause idref="T57"/>
<clue>Triflusal and HTB may exert beneficial effects in processes in which de novo COX-2 expression is involved and, in a broader sense, in pathological situations in which genes under nuclear factor-kappaB <clueType>control</clueType> are up-regulated.</clue>
</event>
<event KT="Other" id="E39">
<type class="Positive_regulation"/>
<theme idref="E38"/>
<clue>Triflusal and HTB may exert beneficial effects in processes in which de novo COX-2 expression is involved and, in a broader sense, in pathological situations in which genes under nuclear factor-kappaB control are up-regulated.</clue>
</event>
<event CL="L1" KT="Analysis" id="E40">
<type class="Regulation"/>
<theme idref="A5"/>
<cause idref="T53"/>
<clue>Triflusal and HTB <clueKT><clueCL>may</clueCL></clueKT> exert beneficial <clueType>effects</clueType> in processes in which de novo COX-2 expression is involved and, in a broader sense, <linkTheme>in</linkTheme> pathological situations in which genes under nuclear factor-kappaB control are up-regulated.</clue>
</event>
<event CL="L1" KT="Analysis" id="E41">
<type class="Regulation"/>
<theme idref="A5"/>
<cause idref="T54"/>
<clue>Triflusal and HTB <clueKT><clueCL>may</clueCL></clueKT> exert beneficial <clueType>effects</clueType> in processes in which de novo COX-2 expression is involved and, in a broader sense, <linkTheme>in</linkTheme> pathological situations in which genes under nuclear factor-kappaB control are up-regulated.</clue>
</event>
</AbstractText>
</Abstract></Article></MedlineCitation></PubmedArticle></PubmedArticleSet></Annotation>
